Welcome to our dedicated page for Hutchmed (China) SEC filings (Ticker: HCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HUTCHMED (China) Limited filings document a foreign private issuer with American depositary shares linked to its ordinary-share capital. Form 6-K submissions furnish press releases, annual report materials, shareholder-meeting documents, total voting-rights notices, and governance disclosures for the company’s Nasdaq, AIM and HKEX-listed securities.
The filing record covers HUTCHMED’s targeted therapy and immunotherapy business, China regulatory updates, oncology and immunology pipeline disclosures, licensed product matters, and annual reporting. Other recurring filing subjects include AGM notices and proxy materials, voting instructions for American depositary share holders, long-term incentive plan award vesting, and capital-structure details for ordinary shares, depositary interests and ADSs.
HUTCHMED (China) Limited reports that Independent Non-executive Director Professor Mok Shu Kam, Tony will retire from the Board at the annual general meeting on May 12, 2026 and will not seek re-election. He has served for more than eight years, approaching the nine-year cap on independent director tenure under Hong Kong Listing Rules.
At the conclusion of the meeting, he will cease to be an Independent Non-executive Director and step down from his roles as chairman and member of the Company’s board committees, including the Nomination and Technical Committees. The Board has approved changes to the composition of board committees and the Senior and Lead Independent Non-executive Director role, effective from the end of the meeting, subject to shareholder re-election of the relevant directors. Professor Mok has confirmed he has no disagreement with the Board and that there are no other matters needing shareholder attention regarding his retirement.
HUTCHMED reported 2025 full-year results with revenue of $548.5 million, down 13% from 2024, and net income of $456.9 million, up sharply from $37.7 million. Profit was boosted by a $415.8 million gain on divesting part of SHPL, alongside lower operating expenses.
Oncology/Immunology consolidated revenue fell 21% to $285.5 million, but total in‑market oncology sales grew 5% to $524.7 million, led by 26% FRUZAQLA® growth. Cash, cash equivalents and short-term investments rose to $1.37 billion, and 2026 Oncology/Immunology revenue guidance is $330–$450 million.
HUTCHMED (China) Limited files its annual report detailing 2025 results and key risks around its China-focused oncology business. The company is a Cayman holding structure with operations run mainly through PRC subsidiaries and 872,327,620 ordinary shares outstanding as of December 31, 2025.
The report highlights dependence on three approved oncology drugs and a large pipeline still in development, alongside heavy R&D spending and a 2025 operating cash outflow of $64.7 million after positive operating cash flows in 2023 and 2024. Equity earnings from its Shanghai Hutchison Pharmaceuticals stake fell 51.3% to $22.7 million in 2025 after divesting 45% of that business.
HUTCHMED flags substantial legal and operational risks from PRC oversight, data and cybersecurity rules, the Holding Foreign Companies Accountable Act, and evolving Chinese approval requirements for offshore offerings. It notes FX controls and PRC dividend restrictions, has never paid dividends, and warns it may need substantial additional capital, which could dilute shareholders or add debt.
HUTCHMED has begun a global Phase I/IIa clinical trial of HMPL-A580, its second next-generation Antibody-Targeted Therapy Conjugate (ATTC), in patients with unresectable, advanced or metastatic solid tumors in China and the US. The first patient was dosed on March 4, 2026.
HMPL-A580 links a highly selective PI3K/PIKK small-molecule inhibitor to an anti-EGFR antibody, aiming to exploit synergy between PAM pathway inhibition and EGFR blockade. The study’s dose-escalation phase will determine the recommended dose, followed by expansion cohorts to further assess safety and preliminary anti-tumor activity.
HUTCHMED (China) Limited has scheduled the release of its 2025 final results for March 5, 2026. The announcement will be made at 6:00 am EST, 11:00 am GMT and 7:00 pm HKT, giving investors in major markets simultaneous access.
Management will host two webcast presentations for analysts and investors to review the results and take questions. An English webcast is set for 8:00 am EST on March 5, 2026, and a Putonghua webcast for the Hong Kong and mainland China audience will follow on March 6, 2026. Live and replay access will be available via the company’s website.
HUTCHMED (China) Limited reports that the Phase III registration part of its ESLIM-02 trial of sovleplenib in adults with warm antibody autoimmune hemolytic anemia (wAIHA) in China met its primary endpoint. The study achieved a durable hemoglobin response rate between weeks 5 and 24, indicating rapid and sustained improvements in red blood cell levels for relapsed or refractory patients.
Earlier Phase II data showed hemoglobin benefits versus placebo with overall response rates of 43.8% vs 0% in the first 8 weeks, and 66.7% over 24 weeks of sovleplenib treatment with a favorable safety profile. HUTCHMED plans to submit a New Drug Application for sovleplenib in wAIHA to China’s NMPA in the first half of 2026 and is also developing the drug for immune thrombocytopenia, where a China Phase III trial has already reported positive results.
HUTCHMED (CHINA) LIMITED filed a Form 6-K to furnish two exhibits. One is an announcement related to a blocklisting six monthly return, which is a routine administrative update. The other is a press release stating that an NDA in China for fanregratinib in second-line intrahepatic cholangiocarcinoma has been accepted with priority review status, signaling a notable regulatory milestone for this cancer therapy candidate.
HUTCHMED (CHINA) LIMITED submitted a Form 6-K indicating it issued a press release about starting global clinical development of its ATTC candidate HMPL-A251 in patients with solid tumors. The report is signed by the Chief Financial Officer, Johnny Cheng, and dated December 17, 2025.
HUTCHMED (CHINA) LIMITED filed a Form 6-K furnishing Exhibit 99.1, a press release about completion of enrollment in the SAFFRON global phase III trial evaluating the combination of ORPATHYS and TAGRISSO for certain lung cancer patients with MET overexpression and/or amplification after progression on TAGRISSO.